CoChat
Sign Up
Cited by 58

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Dysregulated Network of miRNAs Involved in the Pathogenesis of Multiple Sclerosis

Dolati, Sanam, Marofi, Faroogh, Babaloo, Zohreh, Aghebati-Maleki, Leili, Roshangar, Leila, Ahmadi, Majid, Rikhtegar, Reza, Yousefi, Mehdi·2018·Biomedicine & Pharmacotherapy
DOI 10.1016/j.biopha.2018.05.050
Open this paper in CoChat — free account

Abstract

Multiple sclerosis (MS) is a chronic and organ-specific autoimmune disease in which immune cells act against the myelin sheath, resulting in central nervous system (CNS) damage. It has been revealed that miRNAs can play significant role in the pathogenesis of MS. These regulatory molecules lead to the activation of different signaling pathways, regulation of several transcriptional factors, influencing the differentiation of Th17 cells, development of Tregs and alteration from Th2 to Th1 response in MS. New studies have discovered that dysregulation of miRNAs may trigger abnormal immune responses leading consequently in the emergence of autoimmunity. In this review, we have discussed the altered expression patterns of miRNAs discovered in MS patients. These types of dysregulated miRNAs have been associated with MS pathogenesis. Current outcomes propose that such dysregulated miRNAs are potential to serve as useful biomarkers to diagnose MS, and to recognize new healing targets for its treatment.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.biopha.2018.05.050

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 4 references

Research works printed but not linked: 103

  1. Dolati, 2017, Multiple sclerosis: Therapeutic applications of advancing drug delivery systems, Biomedicine & Pharmacotherapy, 86, 343, 10.1016/j.biopha.2016.12.010 · DOI
  2. Popescu, 2012, Pathology of demyelinating diseases, Annual Review of Pathology: Mechanisms of Disease, 7, 185, 10.1146/annurev-pathol-011811-132443 · DOI
  3. Matsui, 2012, Immunology for understanding the pathogenesis of multiple sclerosis, Rinsho shinkeigaku= Clinical neurology, 53, 898, 10.5692/clinicalneurol.53.898 · DOI
  4. Fischer, 2012, NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury, Brain, 135, 886, 10.1093/brain/aws012 · DOI · Paper page
  5. Ahmadi, 2017, Epigenetic modifications and epigenetic based medication implementations of autoimmune diseases, Biomedicine & Pharmacotherapy, 87, 596, 10.1016/j.biopha.2016.12.072 · DOI
  6. Ma, 2014, Expression, regulation and function of microRNAs in multiple sclerosis, International journal of medical sciences, 11, 810, 10.7150/ijms.8647 · DOI
  7. Aslani, 2017, Epigenetic modifications and therapy in multiple sclerosis, Neuromolecular medicine, 19, 11, 10.1007/s12017-016-8422-x · DOI
  8. Gandhi, 2015, miRNA in multiple sclerosis: search for novel biomarkers, Multiple Sclerosis Journal, 10.1177/1352458515578771 · DOI
  9. Ghildiyal, 2010, Sorting of Drosophila small silencing RNAs partitions microRNA* strands into the RNA interference pathway, Rna, 16, 43, 10.1261/rna.1972910 · DOI · Paper page
  10. Moore, 2013, MicroRNA dysregulation in multiple sclerosis, Frontiers in genetics, 3, 311
  11. Otaegui, 2009, Differential micro RNA expression in PBMC from multiple sclerosis patients, PloS one, 4, e6309, 10.1371/journal.pone.0006309 · DOI
  12. Küçükali, 2015, Epigenetics of multiple sclerosis: an updated review, Neuromolecular medicine, 17, 83, 10.1007/s12017-014-8298-6 · DOI
  13. Ingwersen, 2015, Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR‐20b, Annals of clinical and translational neurology, 2, 43, 10.1002/acn3.152 · DOI
  14. Li, 2015, miR-340 inhibits glioblastoma cell proliferation by suppressing CDK6, cyclin-D1 and cyclin-D2, Biochemical and biophysical research communications, 460, 670, 10.1016/j.bbrc.2015.03.088 · DOI
  15. Guerau-de-Arellano, 2011, Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity, Brain, 134, 3578, 10.1093/brain/awr262 · DOI · Paper page
  16. Lindberg, 2010, Altered expression of miR‐17‐5p in CD4+ lymphocytes of relapsing–remitting multiple sclerosis patients, European journal of immunology, 40, 888, 10.1002/eji.200940032 · DOI
  17. Arruda, 2015, Autologous hematopoietic SCT normalizes miR-16,-155 and-142-3p expression in multiple sclerosis patients, Bone marrow transplantation, 50, 380, 10.1038/bmt.2014.277 · DOI
  18. Lorenzi, 2012, miR-15a and 16-1 are downregulated in CD4+ T cells of multiple sclerosis relapsing patients, International Journal of Neuroscience, 122, 466, 10.3109/00207454.2012.678444 · DOI
  19. Tian, 2015, MiRNA-15a inhibits proliferation, migration and invasion by targeting TNFAIP1 in human osteosarcoma cells, International journal of clinical and experimental pathology, 8, 6442
  20. Renjie, 2015, MiR-132, miR-15a and miR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5, Cancer letters, 356, 568, 10.1016/j.canlet.2014.10.003 · DOI
  21. Zubillaga-Guerrero, 2015, MicroRNA miR-16-1 regulates CCNE1 (cyclin E1) gene expression in human cervical cancer cells, International journal of clinical and experimental medicine, 8, 15999
  22. Kang, 2015, Targeting of YAP1 by microRNA-15a and microRNA-16-1 exerts tumor suppressor function in gastric adenocarcinoma, Molecular cancer, 14, 1, 10.1186/s12943-015-0323-3 · DOI
  23. Huang, 2016, MicroRNAs associated with the pathogenesis of multiple sclerosis, Journal of neuroimmunology, 295, 148, 10.1016/j.jneuroim.2016.04.014 · DOI
  24. Smith, 2012, miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis, The Journal of Immunology, 189, 1567, 10.4049/jimmunol.1103171 · DOI
  25. Guerau-de-Arellano, 2011, Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity, Brain, awr262
  26. Yao, 2016, miR-27b is upregulated in cervical carcinogenesis and promotes cell growth and invasion by regulating CDH11 and epithelial-mesenchymal transition, Oncology reports, 35, 1645, 10.3892/or.2015.4500 · DOI
  27. Cruz, 2017, Excessive expression of miR-27 impairs Treg-mediated immunological tolerance, The Journal of clinical investigation, 127, 530, 10.1172/JCI88415 · DOI
  28. Cho, 2016, miR-23∼ 27∼ 24 clusters control effector T cell differentiation and function, Journal of Experimental Medicine, 213, 235, 10.1084/jem.20150990 · DOI
  29. Xu, 2016, MicroRNA-340 mediates metabolic shift in oral squamous cell carcinoma by targeting glucose transporter-1, Journal of Oral and Maxillofacial Surgery, 74, 844, 10.1016/j.joms.2015.09.038 · DOI
  30. Ehya, 2017, Identification of miR-24 and miR-137 as novel candidate multiple sclerosis miRNA biomarkers using multi-staged data analysis protocol, Molecular biology research communications, 6, 127
  31. Tufekci, 2010, MicroRNAs and multiple sclerosis, Autoimmune diseases
  32. De Santis, 2010, Altered miRNA expression in T regulatory cells in course of multiple sclerosis, Journal of neuroimmunology, 226, 165, 10.1016/j.jneuroim.2010.06.009 · DOI
  33. Naghavian, 2015, miR-141 and miR-200a, revelation of new possible players in modulation of Th17/Treg differentiation and pathogenesis of multiple sclerosis, PloS one, 10, e0124555, 10.1371/journal.pone.0124555 · DOI
  34. Severin, 2016, MicroRNAs targeting TGFβ signalling underlie the regulatory T cell defect in multiple sclerosis, Brain, 139, 1747, 10.1093/brain/aww084 · DOI · Paper page
  35. Curtale, 2010, An emerging player in the adaptive immune response: microRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lymphocytes, Blood, 115, 265, 10.1182/blood-2009-06-225987 · DOI · Paper page
  36. Jurkin, 2010, miR-146a is differentially expressed by myeloid dendritic cell subsets and desensitizes cells to TLR2-dependent activation, The Journal of Immunology, 184, 4955, 10.4049/jimmunol.0903021 · DOI · Paper page
  37. Li, 2010, MicroRNA‐146a and Human Disease, Scandinavian journal of immunology, 71, 227, 10.1111/j.1365-3083.2010.02383.x · DOI · Paper page
  38. Zhu, 2014, miR-20b suppresses Th17 differentiation and the pathogenesis of experimental autoimmune encephalomyelitis by targeting RORγt and STAT3, The Journal of Immunology, 192, 5599, 10.4049/jimmunol.1303488 · DOI
  39. Mycko, 2015, miR-155-3p drives the development of autoimmune demyelination by regulation of heat shock protein 40, The Journal of Neuroscience, 35, 16504, 10.1523/JNEUROSCI.2830-15.2015 · DOI · Paper page
  40. Dolati, 2017, Nanocurcumin restores aberrant miRNA expression profile in multiple sclerosis, randomized, double‐blind, placebo‐controlled trial, Journal of cellular physiology
  41. Du, 2009, MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis, Nature immunology, 10, 1252, 10.1038/ni.1798 · DOI · Paper page
  42. Lescher, 2012, MicroRNA regulation in experimental autoimmune encephalomyelitis in mice and marmosets resembles regulation in human multiple sclerosis lesions, Journal of neuroimmunology, 246, 27, 10.1016/j.jneuroim.2012.02.012 · DOI
  43. Zhu, 2012, The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-[alpha], Nature medicine, 18, 1077, 10.1038/nm.2815 · DOI · Paper page
  44. Honardoost, 2014, miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing–remitting multiple sclerosis, Gene, 544, 128, 10.1016/j.gene.2014.04.069 · DOI
  45. Wu, 2017, MicroRNA-448 promotes multiple sclerosis development through induction of Th17 response through targeting protein tyrosine phosphatase non-receptor type 2 (PTPN2), Biochemical and Biophysical Research Communications, 486, 759, 10.1016/j.bbrc.2017.03.115 · DOI
  46. Liu, 2017, MicroRNA-15b suppresses Th17 differentiation and is associated with pathogenesis of multiple sclerosis by targeting O-GlcNAc transferase, The Journal of Immunology, 198, 2626, 10.4049/jimmunol.1601727 · DOI
  47. Sievers, 2012, Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects, Clinical immunology, 144, 70, 10.1016/j.clim.2012.04.002 · DOI
  48. Ventura, 2008, Targeted deletion reveals essential and overlapping functions of the miR-17∼ 92 family of miRNA clusters, Cell, 132, 875, 10.1016/j.cell.2008.02.019 · DOI
  49. Aung, 2014, Decreased Dicer expression is linked to increased expression of co-stimulatory molecule CD80 on B cells in multiple sclerosis, Multiple Sclerosis Journal
  50. Aung, 2015, MMP-9 expression is increased in B lymphocytes during multiple sclerosis exacerbation and is regulated by microRNA-320a, Journal of neuroimmunology, 278, 185, 10.1016/j.jneuroim.2014.11.004 · DOI
  51. Miyazaki, 2014, A novel microRNA-132-surtuin-1 axis underlies aberrant B-cell cytokine regulation in patients with relapsing-remitting multiple sclerosis, PloS one, 9, e105421, 10.1371/journal.pone.0105421 · DOI
  52. Yao, 2015, Hypoxia-Induced Upregulation of miR-132 Promotes Schwann Cell Migration After Sciatic Nerve Injury by Targeting PRKAG3, Molecular Neurobiology, 1
  53. Qi, 2014, MicroRNA‐320a inhibits cell proliferation, migration and invasion by targeting BMI‐1 in nasopharyngeal carcinoma, FEBS letters, 588, 3732, 10.1016/j.febslet.2014.08.021 · DOI
  54. Sun, 2015, MiR-320a acts as a prognostic factor and Inhibits metastasis of salivary adenoid cystic carcinoma by targeting ITGB3, Molecular cancer, 14, 1, 10.1186/s12943-015-0344-y · DOI
  55. Wang, 2015, MicroRNA-320a inhibits proliferation and invasion of breast cancer cells by targeting RAB11A, American journal of cancer research, 5, 2719, 10.1158/1538-7445.AM2015-2719 · DOI
  56. Fontana, 2007, MicroRNAs 17-5p–20a–106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation, Nature cell biology, 9, 775, 10.1038/ncb1613 · DOI · Paper page
  57. Lugli, 2015, Plasma exosomal miRNAs in persons with and without Alzheimer disease: altered expression and prospects for biomarkers, PloS one, 10, e0139233*, 10.1371/journal.pone.0139233 · DOI · Paper page
  58. Ebrahimkhani, 2017, Exosomal microRNA signatures in multiple sclerosis reflect disease status, Scientific Reports, 7, 14293, 10.1038/s41598-017-14301-3 · DOI
  59. Kacperska, 2015, Selected extracellular microRNA as potential biomarkers of multiple sclerosis activity—preliminary study, Journal of Molecular Neuroscience, 56, 154, 10.1007/s12031-014-0476-3 · DOI
  60. Søndergaard, 2013, Differential microRNA expression in blood in multiple sclerosis, Multiple Sclerosis Journal, 19, 1849, 10.1177/1352458513490542 · DOI
  61. Gandhi, 2013, Circulating microRNAs as biomarkers for disease staging in multiple sclerosis, Annals of neurology, 73, 729, 10.1002/ana.23880 · DOI
  62. Fenoglio, 2012, MicroRNAs as active players in the pathogenesis of multiple sclerosis, International journal of molecular sciences, 13, 13227, 10.3390/ijms131013227 · DOI
  63. Sarchielli, 2008, Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patients, Neuroscience letters, 435, 223, 10.1016/j.neulet.2008.02.040 · DOI
  64. Aziz, 2016, The emerging role of miR-223 as novel potential diagnostic and therapeutic target for inflammatory disorders, Cellular immunology, 303, 1, 10.1016/j.cellimm.2016.04.003 · DOI
  65. Fenoglio, 2013, Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis, Multiple Sclerosis Journal, 19, 1938, 10.1177/1352458513485654 · DOI
  66. Vistbakka, 2017, Circulating microRNAs as biomarkers in progressive multiple sclerosis, Multiple Sclerosis Journal, 23, 403, 10.1177/1352458516651141 · DOI
  67. Haghikia, 2012, Regulated microRNAs in the CSF of patients with multiple sclerosis A case-control study, Neurology, 79, 2166, 10.1212/WNL.0b013e3182759621 · DOI
  68. Junker, 2009, MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47, Brain, 132, 3342, 10.1093/brain/awp300 · DOI · Paper page
  69. Bruinsma, 2017, Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS, Journal of neuroinflammation, 14, 235, 10.1186/s12974-017-1006-3 · DOI
  70. Noorbakhsh, 2011, Impaired neurosteroid synthesis in multiple sclerosis, Brain, 134, 2703, 10.1093/brain/awr200 · DOI
  71. Zhang, 2015, Protoporphyrin treatment modulates susceptibility to experimental autoimmune encephalomyelitis in miR-155-deficient mice, PloS one, 10, e0145237, 10.1371/journal.pone.0145237 · DOI
  72. Lopez-Ramirez, 2014, MicroRNA-155 negatively affects blood–brain barrier function during neuroinflammation, The FASEB Journal, 28, 2551, 10.1096/fj.13-248880 · DOI · Paper page
  73. Fernández, 2010, Orchestrating innate immune responses in multiple sclerosis: molecular players, Journal of neuroimmunology, 225, 5, 10.1016/j.jneuroim.2010.05.014 · DOI
  74. Wu, 2015, Brain endothelial miR-146a negatively modulates T-cell adhesion through repressing multiple targets to inhibit NF-κB activation, Journal of Cerebral Blood Flow & Metabolism, 35, 412, 10.1038/jcbfm.2014.207 · DOI
  75. Swaminathan, 2012, Differential regulation of the Let-7 family of microRNAs in CD4+ T cells alters IL-10 expression, The Journal of Immunology, 188, 6238, 10.4049/jimmunol.1101196 · DOI
  76. Mueller, 2014, PreImplantation factor promotes neuroprotection by targeting microRNA let-7, Proceedings of the National Academy of Sciences, 111, 13882, 10.1073/pnas.1411674111 · DOI
  77. Pobezinsky, 2015, Let-7 microRNAs target the lineage-specific transcription factor PLZF to regulate terminal NKT cell differentiation and effector function, Nature immunology, 16, 517, 10.1038/ni.3146 · DOI
  78. Liu, 2013, Let7a inhibits the growth of endometrial carcinoma cells by targeting Aurora‐B, FEBS letters, 587, 2523, 10.1016/j.febslet.2013.05.065 · DOI
  79. Kumar, 2015, MicroRNA let-7 Modulates the Immune Response to Mycobacterium tuberculosis Infection via Control of A20, an Inhibitor of the NF-κB Pathway, Cell host & microbe, 17, 345, 10.1016/j.chom.2015.01.007 · DOI
  80. Joshi, 2016, A cardiac myocyte-restricted Lin28/let-7 regulatory axis promotes hypoxia-mediated apoptosis by inducing the AKT signaling suppressor PIK3IP1, Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1862, 240, 10.1016/j.bbadis.2015.12.004 · DOI
  81. Madison, 2015, Let-7 represses carcinogenesis and a stem cell phenotype in the intestine via regulation of Hmga2, PLoS Genet, 11, e1005408, 10.1371/journal.pgen.1005408 · DOI
  82. Wang, 2017, The identification of up‐regulated ebv‐miR‐BHRF1‐2‐5p targeting MALT1 and ebv‐miR‐BHRF1‐3 in the circulation of patients with multiple sclerosis, Clinical & Experimental Immunology, 189, 120, 10.1111/cei.12954 · DOI
  83. Xia, 2008, EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3, Cancer research, 68, 1436, 10.1158/0008-5472.CAN-07-5126 · DOI
  84. Angelini, 2013, Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis, PLoS pathogens, 9, e1003220, 10.1371/journal.ppat.1003220 · DOI
  85. Backes, 2016, Specific miRNA disease biomarkers in blood, serum and plasma: challenges and prospects, Molecular diagnosis & therapy, 20, 509, 10.1007/s40291-016-0221-4 · DOI
  86. Tkach, 2016, Communication by extracellular vesicles: where we are and where we need to go, Cell, 164, 1226, 10.1016/j.cell.2016.01.043 · DOI · Paper page
  87. Budnik, 2016, Extracellular vesicles round off communication in the nervous system, Nature reviews, Neuroscience, 17, 160
  88. Selmaj, 2017, Global exosome transcriptome profiling reveals biomarkers for multiple sclerosis, Annals of Neurology, 81, 703, 10.1002/ana.24931 · DOI
  89. Mycko, 2012, MicroRNA-301a regulation of a T-helper 17 immune response controls autoimmune demyelination, Proceedings of the National Academy of Sciences, 109, E1248, 10.1073/pnas.1114325109 · DOI
  90. Xu, 2016, B Cell–Activating Transcription Factor Plays a Critical Role in the Pathogenesis of Anti–Major Histocompatibility Complex–Induced Obliterative Airway Disease, American Journal of Transplantation, 16, 1173, 10.1111/ajt.13595 · DOI
  91. Hecker, 2013, MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients, International journal of molecular sciences, 14, 16087, 10.3390/ijms140816087 · DOI
  92. Kimura, 2018, Circulating exosomes suppress the induction of regulatory T cells via let-7i in multiple sclerosis, Nature communications, 9, 17, 10.1038/s41467-017-02406-2 · DOI
  93. Meira, 2014, Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4, Journal of immunology research, 10.1155/2014/897249 · DOI
  94. McCormack, 2013, Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis, Drugs, 73, 1463, 10.1007/s40265-013-0102-7 · DOI
  95. Muñoz-Culla, 2014, Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients, Multiple Sclerosis Journal, 20, 1851, 10.1177/1352458514534513 · DOI
  96. Meira, 2014, MiR-126: a novel route for natalizumab action?, Multiple Sclerosis Journal, 20, 1363, 10.1177/1352458514524998 · DOI
  97. Waschbisch, 2011, Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis, PloS one, 6, e24604, 10.1371/journal.pone.0024604 · DOI
  98. De Felice, 2014, Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β, BMC medical genomics, 7, 1, 10.1186/1755-8794-7-26 · DOI
  99. Potenza, 2018, Human miR-26a-5p regulates the glutamate transporter SLC1A1 (EAAT3) expression. Relevance in multiple sclerosis, Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1864, 317, 10.1016/j.bbadis.2017.09.024 · DOI
  100. Wu, 2017, Dimethyl fumarate selectively reduces memory T cells and shifts the balance between Th1/Th17 and Th2 in multiple sclerosis patients, The Journal of Immunology, 198, 3069, 10.4049/jimmunol.1601532 · DOI
  101. Michell-Robinson, 2016, Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis, Annals of clinical and translational neurology, 3, 27, 10.1002/acn3.270 · DOI
  102. Dolati, 2016, Utilization of nanoparticle technology in rheumatoid arthritis treatment, Biomedicine & Pharmacotherapy, 80, 30, 10.1016/j.biopha.2016.03.004 · DOI
  103. Rostamzadeh, 2016, Application of nanoparticle technology in the treatment of systemic lupus erythematous, Biomedicine & Pharmacotherapy, 83, 1154, 10.1016/j.biopha.2016.08.020 · DOI

Cited by

Sorted by citations

Metadata

Authors
Dolati, S., Marofi, F., Babaloo, Z., Aghebati-Maleki, L., Roshangar, L., Ahmadi, M., Rikhtegar, R., & Yousefi, M.
Venue
Biomedicine & Pharmacotherapy
Publisher
Elsevier BV
Published
2018-08
Volume
104
Pages
280-290
ISSN
0753-3322
DOI
10.1016/j.biopha.2018.05.050
Cited by
58
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review